Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-09-21
Tempus AI, Inc.
Tempus AI combines genomic diagnostics, clinical workflow software, and de-identified data products for healthcare providers and biopharma customers.
ai biotech healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Governed oncology data, with premium expectations attached
A real healthcare AI flywheel exists here: diagnostics create scarce data, data improves products, and products deepen workflow embedding. The investment case now depends less on relevance and more on converting that advantage into recurring, self-funded growth.

Analysis

Thesis
Tempus can outgrow ordinary diagnostics because each added test and workflow relationship creates governed clinical data that can be re-monetized across research, software, and monitoring; the five-year upside is mainly a revenue-quality upgrade, not just more lab volume.
Last Economy Alignment
Cheaper AI raises the value of Tempus' scarce patient-linked data, compliance stack, and workflow embedding; the main limiter is regulator and payer timing, not model access.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.3x (from 5 most recent analyses)
Reasoning
The upside case is a quality-of-growth story. Tempus already has real demand, but the five-year win comes from shifting mix toward higher-value assays, monitoring, and recurring data and workflow revenue. If it proves that data rights are durable and reimbursement improves, investors can keep valuing it above standard lab peers. Because today's valuation is already premium, the realistic win is a doubling-plus outcome, not a moonshot.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is economic conversion. Tempus has a real data and workflow advantage, but it still must turn that into durable, higher-quality revenue faster than regulation, integration, and premium valuation expectations demand. The main swing factors are liquid biopsy timing, Personalis integration, and whether data and applications revenue becomes repeatable rather than lumpy.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.70
They control hard-to-copy patient data rights and sit inside clinical workflows, so cheaper AI makes their information more valuable rather than less. The risk is that regulators, payers, or larger healthcare platforms slow the payoff before the flywheel fully compounds.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$68.18
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case